Sydney, June 15, 2026, 06:01 AEST
- Sigma Healthcare closed Friday at A$2.64, down 1.86%, while the S&P/ASX 200 rose 1.98%.
- The stock is being pulled between strong Chemist Warehouse growth and investor concern over possible large overseas M&A.
- The next key catalyst is a formal company update on the Boots talks, followed by evidence that UK expansion can work without a balance-sheet shock.
Sigma Healthcare Ltd. heads into Monday’s ASX session with investors focused on whether the Chemist Warehouse owner has backed away from a possible acquisition of UK pharmacy giant Boots, after reports over the weekend said shareholder pushback had cooled the company’s appetite for a company-changing deal. Sigma’s shares last traded at A$2.64 on Friday, down 1.86% for the session, even as the S&P/ASX 200 — Australia’s main benchmark index of large listed companies — closed 1.98% higher at 8,804.04.
The immediate issue for the share price is not Boots itself, but what a Boots deal would have meant: a potentially large equity raising, more debt and a major integration challenge just months after Sigma’s merger with Chemist Warehouse. Sigma told the ASX on June 10 that it had held preliminary discussions related to the Boots sale process and said there was no certainty any transaction would eventuate; Reuters reported the same day that the potential sale process could value Boots at about $10 billion, citing the Financial Times report.
The latest twist is that the Australian Financial Review’s Street Talk reported that the deal was off after investors objected to the scale and risk of the mooted UK acquisition. A separate AFN Daily report, citing the AFR, said shareholders were concerned about the size of the transaction, the need for a large equity raising and whether the Chemist Warehouse model had yet been proven in overseas markets. Sigma had not issued a newer ASX announcement on Boots on its investor page after the June 10 statement before the local market opened Monday.
That matters because Sigma’s valuation already asks investors to believe in strong growth and smooth execution. Investing.com data showed Sigma with a market capitalisation of about A$30.37 billion, a 52-week range of A$2.58 to A$3.27 and an EV/EBITDA multiple of 34.51; EV/EBITDA compares a company’s enterprise value, including debt, with earnings before interest, tax, depreciation and amortisation, and a high figure can signal demanding expectations. The stock is only modestly above its 52-week low, showing that investors have become more cautious despite the company’s growth story.
The bull case remains that Sigma’s core business is still growing quickly. In its first-half FY26 result, the company reported revenue of A$5.5 billion, up 14.9%; normalised EBIT of A$582.9 million, up 18.7%; and normalised NPAT of A$392.0 million, up 19.2%. “Normalised” earnings strip out items such as merger-related and integration costs to show underlying performance, while like-for-like sales compare stores that were open in both periods. Sigma said Australian Chemist Warehouse branded store sales rose 17.2%, like-for-like sales rose 15.0%, international retail network sales rose 24.5%, and net debt was only 0.6 times normalised EBITDA.
The bear case is that growth is now tied to several moving parts at once: Chemist Warehouse integration, the Amcal and Discount Drug Stores refresh, international store rollouts, and investor scrutiny over capital allocation. Sigma’s May update showed Australian Chemist Warehouse sales growth of 16.7% for the financial year to April 30 and international store network growth of 24.7% to March 31, but it also confirmed the company’s UK market entry through a GreenLight Healthcare memorandum of understanding, including a planned 75% interest in selected GreenLight stores. That smaller UK step looks easier to digest than Boots, but it still leaves investors watching whether the model travels well.
Analyst consensus is still supportive, but not enough to remove the risk premium. MarketScreener’s latest consensus showed 15 analysts with a “buy” mean rating and an average target price of A$3.333, implying about 26% upside from the A$2.64 last close; Google Finance showed 10 analysts with eight buys, two holds and no sells. The low target near A$2.60, however, sits close to the current price, which suggests the market can still punish the stock if overseas expansion, synergy delivery or trading momentum disappoint. MarketScreener
For now, Sigma looks more fairly valued to risky than clearly cheap. The company has strong verified earnings momentum, a lightly leveraged balance sheet and a still-compelling Chemist Warehouse growth engine, but the stock’s reaction to the Boots speculation shows investors are highly sensitive to dilution and execution risk. The next major catalyst is a definitive ASX update on the Boots process; after that, attention should shift to the FY26 result and whether management can show that synergies, UK trials and international store growth are adding value without forcing shareholders to fund another transformational bet.
